Ιατρικά Άρθρα: 01/26/19

Σάββατο 26 Ιανουαρίου 2019

68 Ga-DOTANOC and 18 F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers

Abstract

Objective

Metastatic disease is common in medullary thyroid carcinoma (MTC) and it is usually detected by raising calcitonin and carcinoembryonic antigen (CEA) levels. Nuclear medicine imaging has an important role in lesion identification/characterisation. We aim to compare ⁶⁸Ga-DOTANOC PET/CT and ¹⁸F-FDG PET/CT performance and to explore the correlations between tumoral markers and functional imaging.

Methods

This a retrospective cross-sectional study including 13 patients with MTC and high calcitonin/CEA levels that underwent both ⁶⁸Ga-DOTANOC PET/CT and ¹⁸F-FDG PET/CT.

Results

⁶⁸Ga-DOTANOC PET/CT identified MTC metastases in 2twopatients that were ¹⁸F-FDG-negative (sensitivity of 69.2% vs. 53.9%, respectively). ⁶⁸Ga-DOTANOC PET/CT also detected a higher number of lesions than ¹⁸F-FDG PET/CT in seven patients, with only one patient showing the opposite pattern. Both differences lacked statistical significance (p = 0.50 and p = 0.86, respectively) but ⁶⁸Ga-DOTANOC PET/CT better performance allowed changes in patients' management. ⁶⁸Ga-positive/¹⁸F-FDG-negative patients were the ones with the lowest calcitonin doubling time and presented a CEA doubling time >24 months, while the patient with more ¹⁸F-FDG-positive lesions was the one with the highest CEA/calcitonin ratio. The number of lesions found in ⁶⁸Ga-DOTANOC PET/CT were correlated with calcitonin levels (r = 0.73; p < 0.01) but not with CEA ones (r = 0.42; p = 0.15). The number of ¹⁸F-FDG hypermetabolic focus were correlated with CEA levels (r = 0.60; p < 0.05) but not with calcitonin (r = 0.48; p = 0.09).

Conclusions

This is the first study to describe a positive correlation between ⁶⁸Ga-positive lesions and calcitonin levels and between ¹⁸F-FDG-positivity and CEA levels. Tumoral markers pattern in metastatic MTC could help clinicians to decide which exam to perform first.

http://bit.ly/2sKzxeN

Correction to: Factors predicting long-term comorbidities in patients with Cushing’s syndrome in remission

The original version of this article unfortunately published with traditional Springer copyright instead of open access under Springer compact agreement.

http://bit.ly/2FSVrnT

The long-term prognosis of heart diseases for different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies

Abstract

Purpose

This meta-analysis aimed to assess the association of different categories of weight and metabolic status with risk of heart diseases including myocardial infarction (MI), cardiovascular diseases (CVDs), and heart failure (HF).

Methods

Data from relevant studies were identified systematically by searching PubMed and Scopus search engines up to 29 May 2018. Prospective studies were included in the analyses with metabolically healthy normal weight (MHNW) as the reference. Pooled RRs and 95% CI were calculated using random-effects or fixed-effect models when appropriate. Subgroup analysis was applied to define possible sources of heterogeneity.

Results

Overall, 21 studies (n = 778,401 participants) were eligible for the present meta-analysis. Generally, the risk of CVDs for all metabolic phenotypes in metabolically unhealthy obese increased compared with the MHNW group. A significant positive association between all metabolic phenotypes and the risk of HF was also observed expect for MHOW (RR = 1.10, 95% CI: 0.60–2.00, P = 0.76) and MHO phenotypes (RR = 0.96, 95% CI: 0.25–3.77, P = 0.95). Moreover, MUHO phenotype was associated with greater risk of MI compared with the MHNW phenotype (RR = 1.82, 95% CI: 1.50–2.22, P < 0.001, respectively).

Conclusions

Our findings showed that all metabolically unhealthy phenotypes in different categories of weight were associated with increased incident of CVDs/HF and MI. Furthermore, healthy overweight and obese subjects had increased risk of CVDs.

http://bit.ly/2RFj9Lk

Hepatic arterial infusion of irinotecan and EmboCept ® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases

Abstract

Intraarterial chemotherapy for colorectal liver metastases (CRLM) can be applied alone or together with embolization particles. It remains unclear whether different types of embolization particles lead to higher intratumoral drug concentration. Herein, we quantified the concentrations of CPT-11 and its active metabolite SN-38 in plasma, liver and tumor tissue after hepatic arterial infusion (HAI) of irinotecan, with or without further application of embolization particles, in a rat model of CRLM. Animals underwent either systemic application of irinotecan, or HAI with or without the embolization particles Embocept^® S and Tandem™. Four hours after treatment concentrations of CPT-11 and SN-38 were analyzed in plasma, tumor and liver samples by high-performance liquid chromatography. Additionally, DNA-damage and apoptosis were analyzed immunohistochemically. Tumor tissue concentrations of SN-38 were significantly increased after HAI with irinotecan and EmboCept^® S compared to the other groups. The number of apoptotic cells was significantly higher after both HAI with irinotecan and EmboCept^® S or Tandem™ loaded with irinotecan compared to the control group. HAI with irinotecan and EmboCept^® S resulted in an increased SN-38 tumor concentration. Both HAI with irinotecan and EmboCept^® S or Tandem™ loaded with irinotecan were highly effective with regard to apoptosis.

http://bit.ly/2Mxl4vN

Meeting report: Metastasis Research Society (MRS) 17th Biennial conference and associated Young Investigator Satellite Meeting (YISM) on cancer metastasis

Abstract

The Metastasis Research Society (MRS) 17th Biennial conference on metastasis was held on the 1st to the 5th of August 2018 at Princeton University, NJ, USA. The meeting was held around themes addressing notable aspects of the understanding and treatment of metastasis and metastatic disease covering basic, translational, and clinical research. Importantly, the meeting was largely supported by our patient advocate partners including Susan G. Komen for the Cure, Theresa's Research Foundation and METAvivor. There were a total of 85 presentations from invited and selected speakers spread across the main congress and presentations from the preceding Young Investigator Satellite Meeting. Presentations are summarized in this report by session topic.

http://bit.ly/2sQnxbG

VideoEndocrinology™ New Open Access Video

Parapharyngeal Dissection for Papillary Thyroid Cancer
Justin Tran, Mark Zafereo

The post VideoEndocrinology™ New Open Access Video appeared first on American Thyroid Association.

http://bit.ly/2T4XFEg

Long-term outcome of hyperthyroidism diagnosed in childhood and adolescence: a single-centre experience

Journal Name: Journal of Pediatric Endocrinology and Metabolism
Issue: Ahead of print

http://bit.ly/2S6JgKK

Hepatopathies in children and adolescents with type 1 diabetes

Journal Name: Journal of Pediatric Endocrinology and Metabolism
Issue: Ahead of print

http://bit.ly/2HA4mgf

Functional and endocrine-metabolic oligomenorrhea: proposal of a new diagnostic assessment tool for differential diagnosis in adolescence

Journal Name: Journal of Pediatric Endocrinology and Metabolism
Issue: Ahead of print

http://bit.ly/2S86xMc

Long-term spatiotemporal variations of atmospheric sulfur, nitrogen and particle pollutants in Chongqing, southwest China: implication of industrial transfer

Abstract

Industrial transfer has swept through in China. However, there is still a knowledge gap about its environmental effects. In this study, industrial transfer status was assessed and evaluated by industrial ratios (%; the gross product contributions of the secondary industry to the whole industry) and the impact of such transfer on atmospheric environment (SO₂, NO₂, PM₁₀ (particles with aerodynamic diameter less than 10 μm), precipitations of SO₄²⁻, NO₃⁻, and NH₄⁺) in the 38 districts and counties in Chongqing was analyzed and discussed for the period of 2006–2015. Results showed that industries were transferred obviously from the main urban region (MUR) into the 1-h economic region (OHER). Atmospheric sulfur and PM₁₀ were efficiently put in control, but atmospheric nitrogen (NO₂; precipitations of NO₃⁻ and NH₄⁺) was increasing and posted a potential threat to air quality especially during 2011–2015. Correlations showed that industrial ratios had significantly positive relationships with concentrations of ambient SO₂ and PM₁₀ in the MUR and ambient NO₂ in the OHER (p < 0.05) while a remarkably negative one with concentrations of ambient SO₂ in the OHER (p < 0.05) during 2006–2015, implying that industrial transfer could be effective in transferring sulfur pollution but not as efficient in transferring atmospheric nitrogen and PM₁₀ pollutions as SO₂ between in the MUR and OHER. More measures should be taken to reduce nitrogen and PM₁₀ emission and a regional monitoring network of ambient NH₃ is in urgent need.

http://bit.ly/2G2LR1z

Real-world drug survival of ixekizumab for psoriasis

Publication date: Available online 26 January 2019

Source: Journal of the American Academy of Dermatology

Author(s): Erica B. Lee, Deeti J. Pithadia, Kelly A. Reynolds, Shivani P. Reddy, Alexander Egeberg, Jashin J. Wu

http://bit.ly/2B2K8pS

Pharmacy Costs of Medications for the Treatment of Onychomycosis in the United States

Publication date: Available online 26 January 2019

Source: Journal of the American Academy of Dermatology

Author(s): Eric J. Yang, Shari R. Lipner

http://bit.ly/2Tkga84

A Comparison of the Efficacy of Ablative Fractional Laser Assisted Photodynamic Therapy according to Ablative Depth for Actinic Keratosis: A Single-blinded, Randomized, Comparative, Prospective Study

Publication date: Available online 26 January 2019

Source: Journal of the American Academy of Dermatology

Author(s): Jeong-Wan Seo, Ho-Jin Kim, Ki-Hoon Song

http://bit.ly/2B60huR

Editorial Board

Publication date: February 2019

Source: Journal of Autoimmunity, Volume 97

Author(s):

http://bit.ly/2HwfavO

Androgens modulate keratinocyte differentiation indirectly through enhancing growth factor production from dermal fibroblasts

Publication date: Available online 26 January 2019

Source: Journal of Dermatological Science

Author(s): Chanat Kumtornrut, Takeshi Yamauchi, Saaya Koike, Setsuya Aiba, Kenshi Yamasaki

Abstract

Background

The main pathogenesis of acne vulgaris is increase in sebum production and abnormal keratinization of the hair infundibulum. The androgens are involved in acne pathogenesis by modulating sebaceous glands to enhance sebum production. However, the molecular mechanisms of abnormal keratinization of the hair infundibulum are not fully elucidated.

Objective

We hypothesized that the androgens affect the dermal fibroblasts, another androgen receptor-positive cells in the skin, resulting in abnormal keratinization through keratinocyte-fibroblast interaction.

Methods

We investigated effects of androgens and estrogens on growth factors expressions by RT-PCR and western blot analysis in human fibroblast (hFB), human keratinocyte (hKC), and fibroblast-keratinocyte co-culture. In vivo, we examined the growth factor expression in acne lesions compared to normal hair follicles by laser-assisted confocal microscope.

Results

In vitro, androgens but not estrogens significantly increased amphiregulin (AREG), epiregulin (EREG), fibroblast growth factor (FGF) 10, and insulin-like growth factor binding protein (IGFBP) 5 mRNA and protein expressions in human fibroblasts but not in keratinocytes. In vivo, AREG, EREG, FGF10, and IGFBP5 were more abundant in acne lesion compared to normal facial skin. FGF10 suppressed cytokeratin 1 and cytokeratin 10 expression in hKC, which was along with the decreased ratio of cytokeratin 10 against cytokeratin 14 in acne lesions compared to normal facial skin. Also, DHT suppressed cytokeratin 1 and cytokeratin 10, in fibroblast-keratinocyte co-culture similarly to the effect of FGF10 to hKC.

Conclusion

These observations suggested that androgens enhance growth factors production from dermal fibroblasts, and growth factors from fibroblasts alter keratinocyte differentiation in acne lesion.

http://bit.ly/2Hvf33P

Rare Risky Recurrent: An Enigmatous Cutaneous Polyp

Myxofibrosarcomas (MFS) are sarcomas most commonly seen in older patients. These are tumors of deep soft tissue seen in subcutaneous tissue, deep fascia with frequent muscle involvement. These sarcomas are notorious for recurrences, progression to a higher grade with notable metastatic potential. It is very often under‐diagnosed owing to its inherent morphological variability. A case of MFS is presented as a cutaneous, exophytic, polypoidal mass because of its rarity and importance of timely diagnosis, as under diagnosis may lead to inadequate clearance of tumor, recurrences, metastases and increased mortality.

http://bit.ly/2HvpMuT

“IgG/IgA Pemphigus in a Patient with a History of Pemphigus Vulgaris: An Example of Epitope Spreading?

The dual presentation of IgG and IgA positivity on direct immunofluorescence (DIF) constitutes a rare form of pemphigus. IgG/IgA pemphigus varies widely in clinical and pathologic presentation. Reported sites of involvement range from the trunk as the sole site of involvement to the whole body and oral mucosa as well as the conjunctiva and esophagus¹.

http://bit.ly/2S9Z5Af

Tissue sodium concentration and sodium T1 mapping of the human brain at 3 T using a Variable Flip Angle method

Publication date: Available online 26 January 2019

Source: Magnetic Resonance Imaging

Author(s): Arthur Coste, Fawzi Boumezbeur, Alexandre Vignaud, Guillaume Madelin, Kathrin Reetz, Denis Le Bihan, Cécile Rabrait-Lerman, Sandro Romanzetti

Abstract

Purpose

The state-of-the-art method to quantify sodium concentrations in vivo consists in a fully relaxed 3D spin-density (SD) weighted acquisition. Nevertheless, most sodium MRI clinical studies use short-TR SD acquisitions to reduce acquisition durations. We present a clinically viable implementation of the Variable Flip Angle (VFA) method for robust and clinically viable quantification of total sodium concentration (TSC) and longitudinal relaxation rates in vivo in human brain at 3 T.

Methods

Two non-Cartesian steady-state spoiled ultrashort echo time (UTE) scans, performed at optimized flip angles, repetition time and pulse length determined under specific absorption rate constraints, are used to simultaneously compute T₁ and total sodium concentration (TSC) maps using the VFA method. Images are reconstructed using the non-uniform Fast Fourier Transform algorithm and TSC maps are corrected for possible inhomogeneity of coil transmission and reception profiles. Fractioned acquisitions are used to correct for potential patient motion. TSC quantifications obtained using the VFA method are validated at first in comparison with a fully-relaxed SD acquisition in a calibration phantom. The robustness of similar VFA acquisitions are compared to the short-TR SD approach in vivo on seven healthy volunteers.

Results

The VFA method resulted in consistent TSC and T₁ estimates across our cohort of healthy subjects, with mean TSC of 38.1 ± 5.0 mmol/L and T₁ of 39.2 ± 4.4 ms. These results are in agreement with previously reported values in literature TSC estimations and with the predictions of a 2-compartment model. However, the short-TR SD acquisition systematically underestimated the sodium concentration with a mean TSC of 31 ± 4.5 mmol/L.

Conclusion

The VFA method can be applied successfully to image sodium at 3 T in about 20 min and provides robust and intrinsically T₁-corrected TSC maps.

http://bit.ly/2FOFKig

Eigenvector-based SPIRiT Parallel MR Imaging Reconstruction based on ℓp pseudo-norm Joint Total Variation

Publication date: Available online 25 January 2019

Source: Magnetic Resonance Imaging

Author(s): Jizhong Duan, Zhongwen Bao, Yu Liu

Abstract

Parallel Magnetic Resonance (MR) imaging is a well-established acceleration technique based on the spatial sensitivities of array receivers. Eigenvector-based SPIRiT (ESPIRiT) is a new parallel MR imaging reconstruction method that combines the advantages of the SENSE and GRAPPA methods. It estimates multiple sets of the sensitivity maps from the calibration matrix that is constructed from the auto-calibration data. To improve the quality of the reconstructed image, we introduced the Total Variation (TV) and ℓ_p pseudo-norm Joint TV (ℓ_pJTV) regularization terms to the ESPIRiT model for parallel MR imaging reconstruction, which were solved by using the Operator Splitting (OS) method. The resulting denoising problems with the TV and ℓ_pJTV regularization terms were solved by exploiting the majorization minimization method. Simulation experiments on two in vivo data sets demonstrated that the proposed OS algorithm with the TV regularization term (OSTV) and OS algorithm with the ℓ_pJTV regularization term (OSℓ_pJTV) outperformed the conventional method with the ℓ₁ regularization term in terms of SNR and NRMSE. And the OSℓ_pJTV algorithm was slightly superior to the OSTV algorithm with the TV regularization term.

http://bit.ly/2G3Eln5

Endoplasmic Reticulum Stress, the Hypothalamus, and Energy Balance

Publication date: Available online 25 January 2019

Source: Trends in Endocrinology & Metabolism

Author(s): Isin Cakir, Eduardo A. Nillni

Overweight and obesity pose significant health problems globally, and are causatively linked to metabolic dysregulation. The hypothalamus integrates neural, nutritional, and hormonal cues to regulate homeostasis, including circadian rhythm, body temperature, thirst, food intake, energy expenditure, and glucose metabolism. Hypothalamic neuropeptides play a fundamental role in these processes. Studies during the past two decades suggest a role of central endoplasmic reticulum (ER) stress in the pathophysiology of obesity. This review covers recent findings on the role of ER stress and neuropeptide processing in the central regulation of energy homeostasis, with special emphasis on proopiomelanocortin (POMC)-encoding neurons. In addition, the role of neuroinflammation in the context of obesity is briefly discussed.

http://bit.ly/2FQhNaj

Sonophotocatalytic treatment of rhodamine B using visible-light-driven CeO 2 /Ag 2 CrO 4 composite in a batch mode based on ribbon-like CeO 2 nanofibers via electrospinning

Abstract

CeO₂/Ag₂CrO₄ composite photocatalyst was successfully fabricated using electrospinning and calcination and chemical precipitation method based on CeO₂ ribbon-like fibers and characterized by field-emission scanning electron microscopy (FESEM), energy dispersive X-ray (EDX), X-ray diffraction (XRD), UV–Vis diffuse reflectance spectroscopy (DRS) and Fourier-transform infrared spectroscopy (FT-IR). The as-obtained CeO₂/Ag₂CrO₄ composite used photocatalytic performance in the sonophotodegradation of rhodamine B in aqueous solution under visible-light (LED) irradiation. DRS analysis illustrates that CeO₂/Ag₂CrO₄ composite exhibited enhanced absorption in the visible region-attributed CeO₂ nanofibers_. The effect of four effective parameters including initial concentration of rhodamine B (RhB), photocatalyst dosage, pH, and irradiation time was studied and optimized using central composite design. The kinetic studies confirmed ability of pseudo first-order reaction based on the Langmuir–Hinshelwood model for fitting empirical data, while its rate constant (k_obs), L–H rate constants (k_r), and L–H adsorption constants (K_A) were 0.0449 min⁻¹, 11.66 mg L⁻¹ min⁻¹ and 1.09E−3 mg L⁻¹, respectively. The enhanced photocatalytic activity could be ascribed to the ultrasound field and formation of a heterojunction system among CeO₂ and Ag₂CrO₄, which lead to a better mass transfer and higher efficiency of charge electron–hole separation, respectively.

http://bit.ly/2B5hBA5

Chironomid genera distribution related to environmental characteristics of a highly impacted basin (Argentina, South America)

Abstract

The objective of the present study was to investigate the responses of the chironomid communities (Diptera: Chironomidae) to environmental variables in four moderately and highly disturbed rivers located in one of the most degraded watersheds in South America. Sampling campaigns were carried out during 2014–2016 in four sites of the Matanza-Riachuelo basin. The physical-chemical and hydrological variables were measured and, the ecological indices were calculated and evaluated by ANOVA. The responses of Chironomidae to the environmental variables were evaluated by redundancy analysis (RDA), and the sampling sites were grouped according to the populations of chironomids and the main environmental variables. Finally, the Spearman correlation was made to determine which of these variables were significant. In total, 13 chironomid taxa were found in 36 samples during the study period. The greatest density registered belongs to Rheotanytarsus and Cricotopus. The ANOVA detected the greatest Chironomidae density and taxonomic richness in the sites with agricultural-urban impact. The changes in the distribution of Rheotanytarsus, Thienemanniella, and Polypedilum were mainly explained by the increase in current velocity, organic matter, and hardness, and the decrease of NH3 and BOD. On the other hand, Goeldichironomus, Chironomus, Parachironomus, Dicrotendipes, and Cricotopus were explained by the increase in conductivity, dissolved oxygen, and temperature, and the decrease of the variables NO3, BOD, and Cu. In addition to this, the sites with urban-agricultural impact were clearly separated from sites with urban-industrial impact. The last one was more related to the increase in BOD, Cu, and NO3 that indicates moderate to poor water quality. In conclusion, we can infer that the physical and chemical variables are correlated with changes in the structure and distribution of the chironomid community and there are genera that respond differently at high and intermediate situations of disturbances. This knowledge contributes to the execution of strategies for the conservation and restoration of the lotic ecosystems.

http://bit.ly/2Tgy1fY

When follow‐up is telling you the truth

Abstract

Over the years, other modified versions of the traditional Mohs surgery have been applied including the perimeter technique (PT). In detail, in our study, the surgical specimen is labeled for margin counting and a further layer including the lesions' bottom is analysed.

http://bit.ly/2WmbrnW

Clinical Trials News

Mon Jan 07, 2019 00:00

Clinical Trials Survey

Would you like to help improve the clinical research experience for patients? We are interested in your opinion about reporting your symptoms for clinical trials. Please click the link below to complete this short, 5-minute survey. Your anonymous responses will be used for research purposes to better understand how to improve patient care. Complete the survey and provide your email address to be entered to win a $100 Visa gift card! Thank you for taking the time to provide your opinion.

ClinicalConnection.com New Clinical Trials

Mon Jan 07, 2019 00:00

Schizophrenia - Princeton NJ

Do you or a loved one suffer from Schizophrenia? If so, Princeton Medical Institute located in Princeton, NJ is conducting a clinical research trial of an investigational treatment for Schizophrenia. We're seeking volunteers 18 to 65 years old who have been diagnosed with Schizophrenia Study-related exams, procedures, and medication are provided at no cost. Visit our website to learn more and submit your interest! Common Symptoms of Schizophrenia May Include: Withdrawal from reality Hallucinations...

ClinicalConnection.com New Clinical Trials

Sun Jan 06, 2019 00:00

Pediatric Plaque Psoriasis - Clearwater FL

Click image to enlargeLocal dermatologists are conducting a clinical research study to test the effectiveness and safety of an investigational topical medication for Plaque Psoriasis.Qualified Participants Must:Be 12-16 years old Provide consent and be accompanied by a legal guardian at the time of consent signing Have an Investigator's Global Assessment (IGA) score of at least 3 Be willing to comply with all study instructions and commit to follow-up visits Females must not be pregnant and agree...

ClinicalConnection.com New Clinical Trials

Fri Jan 04, 2019 00:00

Eczema (Atopic Dermatitis) - Webster TX

Click image to enlarge

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

ADHD with Impulsive Aggression - Grand Prairie TX

Aggression refers to a behavior that can result in both physical and psychological harm to oneself, others or objects in the environment. Aggression is manifested verbally, mentally, and physically. Such behavior becomes maladaptive when it persists, occurs outside an acceptable social context, and is of an intensity, frequency, severity and/or duration detrimental to the child's interests. This is a double-blind, randomized, parallel group, two-arm, placebo-controlled study with flexible dosing...

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

Osteoarthritis of the Knee - La Mesa CA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Woodstock GA

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Excessive Underarm Sweating Study for Children - Raleigh NC

Does Your Child Struggle with Excessive Underarm Sweat?Consider Joining a Clinical Research Study of a New MedicationWake Research is enrolling participants in a study of an investigational medication for excessive underarm sweat in children and teens.

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Phoenix AZ

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Remove ads

Osteoarthritis of the Knee - Albuquerque NM

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Kansas City MO

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Carmichael CA

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Edgewater FL

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - San Angelo TX

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Charleston SC

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Multiple Locations in the US

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Cincinnati OH

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Alzheimer's Disease - Spring Hill FL

If you are caring for someone with Alzheimer's disease, please consider the ROAD clinical research study, which will determine the safety and effectiveness of the multifunctional small moleculeAD-35 in patients with mild to moderate Alzheimer's disease (AD).Key Eligibility Criteria• Between 50 and 85 years of age (inclusive)• Diagnosed with probable AD in accordance with the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria• Mini-Mental State Examination (MMSE) score of ≥>...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Child ADHD - Lakeland FL

Is your child is experiencing the following symptoms: trouble staying focused, interrupts others, hyper or impulsive or does not listen, OR has already been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD)? If yes, learn more about a medical research study evaluating an investigational study drug in children 6 to 17 years of age.

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell responses to a large percentage of neoantigens and to promote antigen spreading and potentially slow progression of prostate cancer, were presented at the 2019 Keystone Symposia on Cancer Vaccines, held January 19-24

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 15:05

Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Strong Pipeline to Boost Growth | Technavio

LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Inhibitors?src=hash" target="_blank"gt;#Inhibitorslt;/agt;--The global PD-1 and PD-L1 Inhibitors market is expected to post a CAGR of over 19% during the period 2019-2023, according to Technavio.

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 14:00

Circassia to buy US, China marketing rights to AIT's AirNOvent

The acquired rights will cover all potential indications in the hospital setting for the administration of inhaled AirNOvent at up to 80 parts per million. One of the The post Circassia to buy US, China marketing rights to AIT's AirNOvent appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression

NV-5138 is a first-in-class, orally-active small molecule that directly activates mTORC1, the gatekeeper of cellular metabolism and renewal, which is suppressed in the brain of people suffering from The post Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

FDA accepts X-Rx's IND application for X-165 to treat IPF

X-165 is a highly potent and selective small molecule inhibitor of Autotaxin owned by X-Rx. An initial advanced lead series that led to the identification of X-165 was The post FDA accepts X-Rx's IND application for X-165 to treat IPF appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

EC approves Clovis' Rubraca to treat women with relapsed ovarian cancer

The second indication of Rubraca has been approved as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer The post EC approves Clovis' Rubraca to treat women with relapsed ovarian cancer appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 06:56

ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results. Management will also provide a brief update on the business. Conference Call InformationTo access the live call by phone, dial 323-794-2093; the conference ID is 6271602. The call may also be a

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:30

Immunomic to Present at the 2019 BIO CEO & Investor Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its' founder and CEO, William Hearl, Ph.D., will present an overview of the company and its UNITE technology platform at the 2019 BIO CEO & Investor Conference on February 12, 2019 at 2:00 pm EST in the Hudson/Empire Room at the Marriott Marquis in New York City. About UNITE ITI's investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Assoc

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:05

Vermont Collaborative Partners with Netsmart to Alter Trajectory of Care for State's Most Vulnerable

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Four member agencies of Vermont Care Partners (VCP) have come together to reshape the delivery and coordination of care through a partnership with Netsmart to deploy a unified technology platform. As value-based care quickly becomes reality, Lamoille County Mental Health Services, Northwestern Counseling and Support Services, United Counseling Services of Bennington and Washington County Mental Health Services will leverage the full suite of solutions from

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 22:00

Remove ads

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation...

Blood CLINICAL TRIALS AND OBSERVATIONS

Thu Jan 24, 2019 19:00

Oyster Point Pharma to Present at the BIO CEO & Investor Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma to present a corporate overview at the BIO CEO & Investor Conference.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 17:33

Midwest Vision Research Foundation at Pepose Vision Institute Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts

ST. LOUIS, Mo.--(BUSINESS WIRE)--Midwest Vision Research Foundation at Pepose Vision Institute joins the AcuFocus IC-8® Lens clinical study for cataracts.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:05

Tamr Joins Accenture's Life Sciences Ecosystem to Help Drive Innovation in Drug Discovery and Scientific Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tamr Inc. today announced it has joined Accenture's open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more effectively to accelerate drug discovery efforts and improve patient outcomes. The ecosystem is an integral part of Accenture's cloud-based informatics research platform, which has been designed to help life sciences organizations improve productivity, efficiency, and innovation in drug discovery.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:00

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting

BOSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell announces data from NAM-NK and NiCord® programs to be presented at 2019 TCT Annual Meeting

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:32

X-Rx Announces FDA Acceptance of IND Application for X-165

WALTHAM, Mass.--(BUSINESS WIRE)--X-Rx Announces FDA Acceptance of IND Application for X-165

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:15

Can-Fite BioPharma CEO Letter to Shareholders

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Pnina Fishman, Chief Executive Officer of Can-Fite Biopharma, has issued a Letter to Shareholders, the full text of which follows below. Dear Can-Fite Shareholders, It has been a very busy and productive year at Can Fite BioPharma, filled with c

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30

Dicerna Evolves Its Board of Directors to Support Continued Growth

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna announced several changes to its board of directors, reflecting the company's ongoing growth.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30

Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer

BURLINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;--ArQule, Inc.'s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche's PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®),...

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;--Concert began a Phase 1 single-ascending dose trial to evaluate the safety, tolerability, and PK profile of CTP 692 in healthy volunteers.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt;--Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 13:59

BridgeBio Pharma raises $299.2m in financing round

BridgeBio Pharma will also use the funds to expand its efforts on the development of medicines for patients with unmet needs. Both existing investors KKR and Viking Global The post BridgeBio Pharma raises $299.2m in financing round appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 13:17

Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463

Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an important milestone for The post Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463 appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 11:20

BioNTech to acquire MAB Discovery's antibody generation unit

Under the terms of the agreement, BioNTech will acquire all assets, employees and proprietary know-how for mAb generation from MAB Discovery. MAB Discovery will retain ownership of and The post BioNTech to acquire MAB Discovery's antibody generation unit appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 13:17

ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorisation (CMA) Application for ANCA-Associated Vasculitis in Europe, Phase III Advocate Trial Data Release Planned for Q4 2019

ZURICH & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Regulatory News: ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd., a company of Vifor Pharma Group, today announced that in light of the upcoming availability of data from the pivotal Phase III ADVOCATE trial – the largest controlled trial in active anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA-associated vasculitis) – they have decided to withdraw the application for Conditional Marketing Authorisation (CM

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 08:00

Gossamer Bio Announces Commencement of Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") in connection with the commencement of a proposed initial public offering of its common stock. Gossamer Bio is offering 14,375,000 sha

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 00:24

Advaxis' Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.S. Food and Drug Administration (FDA) that the Company's ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV) has been placed on partial clinical

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:05

Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders. Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an im

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:01

Vedanta Biosciences Announces Publication in Nature of Seminal Research Revealing A New Mechanism of Human Microbiota-Driven Antitumor Immunity Involving Induction of IFNy+ CD8+ T Cell Accumulation in the Gut and Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences announced a publication in Nature that revealed a newly discovered mechanism underlying antitumor immunity.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 20:07

Remove ads

Modulated Imaging Raises $7M in Series B Funding

IRVINE, Calif.--(BUSINESS WIRE)--Modulated Imaging has raised $7 million in Series B funding to fund the commercialization of its Clarifi technology and clinical studies.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:30

Vascular Dynamics Names Prof. Martin Rothman Chief Medical Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--World-renowned interventional cardiologist Martin Rothman has been named chief medical officer at VDI.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:05

Redx gets regulatory nod to restart RXC004 clinical trial

An oral porcupine inhibitor, RXC004 has been designed to target the Wnt signaling pathway. The early-stage trial of the small molecule drug was temporarily stopped in March 2018 The post Redx gets regulatory nod to restart RXC004 clinical trial appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 17:43

U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology

VIENNA, Va.--(BUSINESS WIRE)--U.S. patent office issues CEL-SCI two patents for its LEAPS vaccine platform technology.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 16:20

Medidata Joins the World Economic Forum

NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MDSO?src=hash" target="_blank"gt;#MDSOlt;/agt;--Medidata (NASDAQ:MDSO) today announced that it has entered into a three-year strategic collaboration with the World Economic Forum. The company becomes a Partner Member Associate and will participate in the WEF System Initiative focused on Shaping the Future of Health and Healthcare. The initiative has a goal of transforming the continuum of care – from prevention to diagnosis, treatment,...

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:30

Ferring Pharmaceuticals appoints Sophie Opdyke to lead its new U.S. oncology division

PARSIPPANY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Ferring?src=hash" target="_blank"gt;#Ferringlt;/agt;--Sophie Opdyke, Pharm.D., MBA, will be responsible for building the Ferring Pharmaceuticals (U.S.) oncology division

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:25

InGeneron Expands Development Pipeline with Two Osteoarthritis Programs

HOUSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/backpain?src=hash" target="_blank"gt;#backpainlt;/agt;--InGeneron expands development pipeline with two studies for chronic backpain and wrist osteoarthritis, setting focus on orthopedic indications.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

PALO ALTO, Calif.--(BUSINESS WIRE)--BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR and Viking Global Investors. Other existing investors participating included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital; and they were joined by new investors Sequoia Capital, and a blue-chip long-term investor. The financing wil

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00

Talee Bio Announces $4.5 Million Award from the Cystic Fibrosis Foundation to Advance Development of Two Gene Therapy Product Candidates

PHILADELPHIA--(BUSINESS WIRE)--Talee Bio, Inc., a development stage biopharmaceutical company focused on developing gene therapy treatments for cystic fibrosis, today announced agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102. The CF Foundation committed up to $4.5 million to expedite the development of both product candidates for all people with cystic fibrosis, and par

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company's board of directors. "We are extremely pleased to add these two experienced executives to Sage's board of directors. As Sage continues to advance its programs in development, adding an executive

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

Triumvira Announces Build out of Senior Management Team with Addition of Industry-Experienced Professionals in R&D and Business Development

AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira appoints Andreas Bader as Senior Vice President of Research & Development and Joshua Carle as Vice President of Business Development.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model

LOS ANGELES--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Breastfeeding?src=hash" target="_blank"gt;#Breastfeedinglt;/agt;--Supplementation with unique B3 vitamin nicotinamide riboside confers significant and enduring physiological benefits to mouse mothers and offspring.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:30

Idiopathic Pulmonary Fibrosis Report - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Idiopathic Pulmonary Fibrosis . The report includes information of marketed products including their product des

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:24

EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL

The approval was based on data from the Phase 2 BLAST study in frontline and relapsed/refractory ALL, the largest prospective trial for MRD-positive ALL ever conducted. BLINCYTO, a The post EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease

RP-A501 is the Company's first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of The post Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

GSK closes acquisition of Tesaro for $5.1bn

Tesaro acquisition will enable GSK to strengthen its pharmaceutical business; and expand its pipeline and commercial capability in oncology. Tesaro president and COO Dr Mary Lynne Hedley said: The post GSK closes acquisition of Tesaro for $5.1bn appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of ordinary shares sold in the offering at the pu

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 23:01

LabCorp Named to FORTUNE Magazine's 2019 List of 'World's Most Admired Companies,' Making the Annual List for the Second Consecutive Year

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2019 List of World's Most Admired Companies, making the annual list for the second consecutive year. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, is given to top executives, directors, and financial analysts to identify the companies that enjoy the strongest reputations within their indust

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 17:35

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell and Be The Match BioTherapies® announced a collaboration to improve outcomes for patients undergoing bone marrow transplantation.

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:30

Bio-Thera Solutions Announces Initiation of Phase III Clinical Trial for BAT1806, a Proposed Biosimilar of Actemra® (Tocilizumab)

GUANGZHOU, China--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/arthritis?src=hash" target="_blank"gt;#arthritislt;/agt;--Bio-Thera Solutions announces the initiation of a Phase III clinical trial for BAT1806, a proposed biosimilar of Actemra® (Tocilizumab).

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:08

Remove ads

LabConnect Announces Global Sample Processing Network

SEATTLE--(BUSINESS WIRE)--LabConnect is pleased to announce a new service: LabConnect's global sample processing network (GSPN).

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, February 7, 20191:30 p.m. Pacific Time / 4

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Rainier Therapeutics Announces Oral Abstract Presentation on Fierce 21 Phase 2 Trial of Vofatamab in Metastatic Urothelial Cell Carcinoma (Bladder Cancer) at the 2019 ASCO Genitourinary Cancers Symposium

SAN LEANDRO, Calif.--(BUSINESS WIRE)--Data from ongoing P2 trial of Rainier's FGFR3-targeted antibody vofatamab to be presented at 2019 ASCO Genitourinary Cancers Symposium Feb 14 in SF

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Resumen: Gore presenta en Europa la endoprótesis para aorta torácica adaptable GORE® TAG® con perfiles reducidos

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha introducido hoy perfiles reducidos para los diámetros más utilizados de la endoprótesis para aorta torácica adaptable GORE® TAG® con el sistema de CONTROL ACTIVO. El perfil reducido permite a los médicos realizar reparaciones endovasculares torácicas (TEVAR) en pacientes con vasos más pequeños donde el acceso es difícil y la anatomía aórtica es tortuosa, lo que amplía la disponibilidad de la endoprótesis para aorta

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47

Samenvatting: Gore introduceert GORE® TAG® Conformable Thoracic Stent Graft met gereduceerde profielen in Europa

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) introduceerde vandaag gereduceerde profielen voor de meest gebruikte diameters van de GORE® TAG® Conformable Thoracic Stent Graft met ACTIVE CONTROL System. Het gereduceerde profiel stelt artsen in staat om TEVAR uit te voeren bij patiënten met kleinere vaten waar de toegang moeilijk is en de aorta anatomie kronkelig is, waardoor de beschikbaarheid van Gore's thoracale stenttransplantaat wordt uitgebreid naar een groter

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47

Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

WILMINGTON, Del.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24INCY&src=ctag" target="_blank"gt;$INCYlt;/agt;--Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:30

Data Presented at LINC Confirm the Safety and Effectiveness of Zilver® PTX®

BLOOMINGTON, Ind.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cookmedical?src=hash" target="_blank"gt;#cookmedicallt;/agt;--Today at the Leipzig Interventional Course (LINC), Cook Medical participated in significant discussion about the use of paclitaxel to treat patients suffering from PAD. Through several presentations to meeting attendees, data supported the use of paclitaxel-coated devices to help the more than 200 million1 patients globally who are fighting the disease. "We believe...

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:10

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerate

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/AlopeciaAreata?src=hash" target="_blank"gt;#AlopeciaAreatalt;/agt;--Concert completed enrollment in its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata.

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Immunochina Raises $20.4 Million USD in Series C Financing

BEIJING--(BUSINESS WIRE)--Beijing-based Immunochina Pharmaceuticals today announced the closing of its $140 million RMB Series C financing (approximately $20.4 million in US Dollars). This financing will enable the company to expand its GMP-grade manufacturing capabilities while continuing clinical trials for its lead IM19 product targeting B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Non Hodgkin's Lymphoma, as well as advancing the development of its pipeline targeting multiple solid and li

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Aplastic Anemia - Pipeline Insight, 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Aplastic Anemia - Pipeline Insight, 2019" drug pipelines report has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Aplastic Anemia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, assoc

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:40

Cluster Headache Syndrome - Pipeline Insight, 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cluster Headache Syndrome - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cluster Headache Syndrome development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:34

TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products

GLASGOW, Scotland--(BUSINESS WIRE)--TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma Delta T (GDT) cell therapies, today announced it has completed formulation of its first allogeneic GDT cell banks. The T cell banks provide TCB with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different cancer types, both hematological and solid tumors. The project was supported by funding from the European Uni

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 12:55

Rationale and study design of the MyHEART study: A young adult hypertension self-management randomized controlled trial

Publication date: Available online 21 January 2019Source: Contemporary Clinical TrialsAuthor(s): Heather M. Johnson, Lisa Sullivan-Vedder, KyungMann Kim, Patrick E. McBride, Maureen A. Smith, Jamie N. LaMantia, Jennifer T. Fink, Megan R. Knutson Sinaise, Laura M. Zeller, Diane R. LauverAbstractYoung adults (18–39 year-olds) with hypertension have a higher lifetime risk for cardiovascular disease. However, less than 50% of young adults achieve hypertension control in the United States. Hypertension...

ScienceDirect Publication: Contemporary Clinical Trials

Tue Jan 22, 2019 13:13

EC approves Vertex's CF treatment Orkambi for children aged two to five years

The label extension has been granted to treat the most common form of CF based on data from a phase 3 open-label safety study in 60 patients. According The post EC approves Vertex's CF treatment Orkambi for children aged two to five years appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Nash's NASH NP-160 shows repeated positive results in second pre-clinical study

In addition, a second compound, NP-135 was identified as an additional lead. Both NP-135 and NP-160 are one of a number of already approved compounds that Nash has The post Nash's NASH NP-160 shows repeated positive results in second pre-clinical study appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Global Clinical Trials 2007-2018: Current Trends and Recent Advancements - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Clinical Trials - Current Trends and Recent Advancement" report has been added to ResearchAndMarkets.com's offering. "Global Clinical Trials Current Trends and Recent Advancement", provides an in-depth assessment of the current trends in the number of clinical trials globally, Top 10 therapy area, geography wise clinical trials, YOY clinical trials in top 10 therapy area. An overview of clinical guidelines reforms has also been provided to show how regulator

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:17

PredictImmune Confirms Canadian Patent Grant

CAMBRIDGE, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IBD?src=hash" target="_blank"gt;#IBDlt;/agt;--PredictImmune confirm Canadian patent grant which covers PredictImmune's intellectual property relating to methods for predicting autoimmune disease

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:00

PCI announces further investment in infrastructure for packaging of controlled substances

PCI has extended onsite controlled substance storage at its US commercial packaging locations in Philadelphia, PA and Rockford, IL, and will undertake further expansions as demand increases for The post PCI announces further investment in infrastructure for packaging of controlled substances appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Remove ads

Wren Therapeutics Completes £18 Million Series A Financing

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Wren Therapeutics ("Wren"), a biopharmaceutical company focused on drug discovery and development for protein misfolding diseases, today announces it has completed a Series A financing round. The company, formally founded in 2016, raised a total of £18 million from an international syndicate led by The Baupost Group with participation from LifeForce Capital and a number of high net worth individual investors. Protein molecules form the machinery that

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:30

EMMAC Life Sciences PLC: Acquisition of a Majority Interest in Medalchemy, a GMP Certified Laboratory, in Alicante Spain

LONDON--(BUSINESS WIRE)--EMMAC, the European independent medical cannabis company, is pleased to announce the acquisition of a majority interest in Medalchemy, a fully-licensed GMP certified laboratory in Alicante, Spain. Medalchemy, a technology-based manufacturing company located on the premises of the University of Alicante, has more than a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs) and has submitted license applications to i

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:00

Updated Analysis of Pivotal Study Reveals: Proactive, High Dosage of Venofer® Significantly Reduces Risk of Death or Major Cardiovascular Events in Haemodialysis Patients

ZURICH--(BUSINESS WIRE)--Re-analysis of pivotal study reveals: Proactive, High DOSAGE OF venofer®...

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00

Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women's health and gastroenterology. The collaboration brings together specialist expertise from Karolinska Institutet in early stage research, Rebiotix Inc. (acquired by Ferring in 2018), a late-stage clinical microbiome company, and Ferring's therapeutic area and co

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00

Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes

January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc., Fairview Health Services, and University of Minnesota Health announced today that for the first time cancer patients are using digital...

Drugs.com - Clinical Trials

Thu Jan 17, 2019 22:01

Two Positive Phase III studies of Tafenoquine for the Radical Cure of Plasmodium vivax Malaria Published in The New England Journal of Medicine

London UK; Philadelphia US; Geneva Switzerland - January 16, 2019 -- GSK and Medicines for Malaria Venture (MMV) today announced the publication of positive results from two phase III studies of single-dose tafenoquine for the radical cure...

Drugs.com - Clinical Trials

Wed Jan 16, 2019 23:01

vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study

HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small...

Drugs.com - Clinical Trials

Wed Jan 16, 2019 22:01

Amgen Makes All Repatha (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at...

Drugs.com - Clinical Trials

Mon Jan 07, 2019 22:01

Gore führt GORE® TAG® Conformable Thoracic Stent Graft mit reduzierten Profilen für die Vermarktung in Europa ein

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) meldete heute die Markteinführung reduzierter Profile für die am häufigsten verwendeten Durchmesser von GORE® TAG® Conformable Thoracic Stent Graft mit ACTIVE CONTROL System. Das reduzierte Profil ermöglicht es den Ärzten, bei Patienten mit kleineren Blutgefäßen eine thorakale endovaskuläre Aortenreparatur (TEVAR) durchzuführen, wenn der Zugang anspruchsvoll und die Aorta gewunden ist, um auf diese Weise die Einsatzmö

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 22:37

Gore lance sur le marché européen GORE® TAG®, une endoprothèse thoracique conformable à profils réduits

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) a présenté aujourd'hui des profils réduits des diamètres les plus couramment utilisés de l'endoprothèse thoracique conformable implantable GORE® TAG® dotée du système ACTIVE CONTROL. La réduction du profil permet aux médecins de procéder à une procédure TEVAR (réparation endovasculaire des anévrismes de l'aorte thoracique) chez les patients dont les vaisseaux sont étroits et difficiles d'accès et l'anatomie aortique t

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 19:30

Riassunto: Gore lancia in Europa lo stent graft toracico conformabile GORE® TAG® con profili ridotti

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha oggi lanciato profili ridotti per i diametri più comunemente utilizzati dello stent graft toracico conformabile GORE® TAG® con sistema ACTIVE CONTROL. Il profilo ridotto consente al personale medico di eseguire trattamenti endovascolari dell'aorta toracica (TEVAR) nei pazienti con vasi sanguigni più piccoli, di difficile accesso e con anatomia aortica tortuosa, ampliando la disponibilità dello stent graft toracico di

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 16:18

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 14:00

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. "Today's approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF," said Reshma K

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 11:00

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 10:00

Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism

Promentis is developing SXC-2023 along with other compounds that engage System xc-, a central nervous system target addressing glutamatergic imbalance and oxidative stress, to treat trichotillomania and other The post Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 12:58

Kyn Therapeutics, Celgene partner on immuno-oncology therapies development

The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet The post Kyn Therapeutics, Celgene partner on immuno-oncology therapies development appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 09:02

Lilly's second immune-oncology candidate using Zymeworks' Azymetric platform to start clinical trials

In accordance with Zymeworks' 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly's submission of an IND application for The post Lilly's second immune-oncology candidate using Zymeworks' Azymetric platform to start clinical trials appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 12:58

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

TOKYO--(BUSINESS WIRE)--At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the "Company") resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the "Group" refers to two companies, SanBio Co., Ltd., and SanBio, Inc.) 1. Details of the Decision As part of its mission to introduce new therapeutic drugs for the central nervous system,

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 02:05

Design of a randomized trial testing a multi-level weight-control intervention to reduce obesity and related health conditions in low-income workers

Publication date: Available online 19 January 2019Source: Contemporary Clinical TrialsAuthor(s): Richard I. Stein, Jaime R. Strickland, Rachel G. Tabak, Ann Marie Dale, Graham A. Colditz, Bradley A. EvanoffAbstractWeight-control is a major public health focus for preventing multiple obesity-related health conditions. While clinic-based intensive lifestyle interventions are successful, low-socioeconomic-status (SES) populations, which have a higher burden of obesity, are difficult to reach; thus,...

ScienceDirect Publication: Contemporary Clinical Trials

Sun Jan 20, 2019 13:44

Ετικέτες

Σάββατο 26 Ιανουαρίου 2019

Abstract

Objective

Methods

Results

Conclusions

Abstract

Purpose

Methods

Results

Conclusions

Abstract

Abstract

Abstract

Abstract

Background

Objective

Methods

Results

Conclusion

Abstract

Purpose

Methods

Results

Conclusion

Abstract

Abstract

Abstract

Abstract

Αναζήτηση αυτού του ιστολογίου